Advanced search
Publication Cover
Acta Cardiologica Volume 77, 2022 - Issue 4
Submit an article Journal homepage
249
Views
1
CrossRef citations to date
0
Altmetric
Original Scientific Papers

Specific FSTL1 polymorphism may determine the risk of cardiomyopathy in patients with acromegaly

Suleyman Nahit Sendura Department of Endocrinology & Metabolism, Hacettepe University School of Medicine, Ankara, TurkeyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6740-6708View further author information
ORCID Icon,
Tuncay Hazirolanb Department of Radiology, Hacettepe University School of Medicine, Ankara, TurkeyORCID Iconhttps://orcid.org/0000-0001-8905-1768View further author information
ORCID Icon,
Busra Aydinc Department of Medical Genetics, Hacettepe University School of Medicine, Ankara, TurkeyView further author information
,
Incilay Layd Department of Medical Biochemistry, Hacettepe University School of Medicine, Ankara, TurkeyORCID Iconhttps://orcid.org/0000-0002-1466-5746View further author information
ORCID Icon,
Mehmet Alikasifogluc Department of Medical Genetics, Hacettepe University School of Medicine, Ankara, TurkeyView further author information
&
Tomris Erbasa Department of Endocrinology & Metabolism, Hacettepe University School of Medicine, Ankara, TurkeyView further author information
Pages 350-359 | Received 24 Feb 2021, Accepted 21 Jun 2021, Published online: 08 Jul 2021

References

  • Katznelson L, Laws ER, Jr., Melmed S, Endocrine Society, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933–3951.
  • Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2008;93(1):61–67.
  • Ritvonen E, Loyttyniemi E, Jaatinen P, et al. Mortality in acromegaly: a 20-year follow-up study. Endocrine Relat Cancer. 2016;23(6):469–480.
  • Delafontaine P. Insulin-like growth factor I and its binding proteins in the cardiovascular system. Cardiovasc Res. 1995;30(6):825–834.
  • Fu ML, Tornell J, Schulze W, et al. Myocardial hypertrophy in transgenic mice overexpressing the bovine growth hormone (bGH) gene. J Intern Med. 2000;247(5):546–552.
  • Ito H, Hiroe M, Hirata Y, et al. Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation. 1993;87(5):1715–1721.
  • Cittadini A, Ishiguro Y, StröMer H, et al. Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitizing the myofilament to Ca2+ through a wortmannin-sensitive pathway: studies in rat and ferret isolated muscles. Circulation Res. 1998;83(1):50–59.
  • Freestone NS, Ribaric S, Mason WT. The effect of insulin-like growth factor-1 on adult rat cardiac contractility. Mol Cell Biochem. 1996;163–164:223–229.
  • Hejtmancik MR, Bradfield JY, Jr., Herrman GR. Acromegaly and the heart: a clinical and pathologic study. Ann Intern Med. 1951;34(6):1445–1456.
  • Lie JT. Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. Am Heart J. 1980;100(1):41–52.
  • Ramos-Levi AM, Marazuela M. Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management. Endocrine. 2017;55(2):346–359.
  • Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25(1):102–152.
  • Erbas T, Erbas B, Usman A, et al. Assessment of left ventricular dysfunction in acromegalic patients using radionuclide ventriculography parameters. Cardiology. 1992;80(3-4):172–179.
  • Chiba A, Watanabe-Takano H, Miyazaki T, et al. Cardiomyokines from the heart. Cell Mol Life Sci. 2018;75(8):1349–1362.
  • Shibanuma M, Mashimo J, Mita A, et al. Cloning from a mouse osteoblastic cell line of a set of transforming-growth-factor-beta 1-regulated genes, one of which seems to encode a follistatin-related polypeptide. Eur J Biochem. 1993;217(1):13–19.
  • Zwijsen A, Blockx H, Van Arnhem W, et al. Characterization of a rat C6 glioma-secreted follistatin-related protein (FRP). Cloning and sequence of the human homologue. Eur J Biochem. 1994;225(3):937–946.
  • Mattiotti A, Prakash S, Barnett P, et al. Follistatin-like 1 in development and human diseases. Cell Mol Life Sci. 2018;75(13):2339–2354.
  • Shimano M, Ouchi N, Nakamura K, et al. Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload. Proc Natl Acad Sci USA. 2011;108(43):E899–906.
  • Tanaka K, Valero-Munoz M, Wilson RM, et al. Follistatin like 1 Regulates Hypertrophy in Heart Failure with Preserved Ejection Fraction. JACC Basic Transl Sci. 2016;1(4):207–221.
  • Wei K, Serpooshan V, Hurtado C, et al. Epicardial FSTL1 reconstitution regenerates the adult mammalian heart. Nature. 2015;525(7570):479–485.
  • Xiao Y, Zhang Y, Chen Y, et al. Inhibition of microRNA-9-5p protects against cardiac remodeling following myocardial infarction in mice. Hum Gene Ther. 2019;30(3):286–301.
  • Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317(17):1098.
  • American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S13–s27.
  • Flack JM, Calhoun D, Schiffrin EL. The new ACC/AHA hypertension guidelines for the prevention, detection, evaluation, and management of high blood pressure in adults. Am J Hypertens. 2018;31(2):133–135.
  • Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation. 2018;139(25):e1082–e1143.
  • Liu Y, Han X, Yu Y, et al. A genetic polymorphism affects the risk and prognosis of renal cell carcinoma: association with follistatin-like protein 1 expression. Sci Rep. 2016;6:26689.
  • Wang Y, Li D, Xu N, et al. Follistatin-like protein 1: a serum biochemical marker reflecting the severity of joint damage in patients with osteoarthritis. Arthritis Res Ther. 2011;13(6):R193.
  • Horak M, Kuruczova D, Zlamal F, et al. Follistatin-like 1 is downregulated in morbidly and super obese Central-European population. Dis Markers. 2018;2018:4140815.
  • Xu X, Zhang T, Mokou M, et al. Follistatin-like 1 as a novel adipomyokine related to insulin resistance and physical activity. J Clin Endocrinol Metab. 2020;105(12):e4499–e4509.
  • Park K, Ahn CW, Park JS, et al. Circulating myokine levels in different stages of glucose intolerance. Medicine. 2020;99(8):e19235.
  • Marcu CB, Nijveldt R, Beek AM, et al. Delayed contrast enhancement magnetic resonance imaging for the assessment of cardiac disease. Heart Lung Circ. 2007;16(2):70–78.
  • Bogazzi F, Lombardi M, Strata E, et al. High prevalence of cardiac hypertophy without detectable signs of fibrosis in patients with untreated active acromegaly: an in vivo study using magnetic resonance imaging. Clin Endocrinol. 2008;68(3):361–36.
  • dos Santos Silva CM, Gottlieb I, Volschan I, et al. Low frequency of cardiomyopathy using cardiac magnetic resonance imaging in an acromegaly contemporary cohort. J Clin Endocrinol Metab. 2015;100(12):4447–4455.
  • Devoitille A, Beckers A, Piérard LA. Clinical case of the month. Cardiac complications of acromegaly: a rare cause of dilated cardiomyopathy. Rev Med Liege. 2012;67(4):174–178.
  • Bihan H, Espinosa C, Valdes-Socin H, et al. Long-term outcome of patients with acromegaly and congestive heart failure. J Clin Endocrinol Metab. 2004;89(11):5308–5313.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Committed to improving the lives of patients with Type 2 Diabetes, Heart Failure and Chronic Kidney Disease.
A bold vision to stop cardiovascular disease from being a leading cause of death.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.